Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 17, 2026

How Much the Top 5% Pay in Taxes in Every State

View original at finance.yahoo.com
How Much the Top 5% Pay in Taxes in Every State The percentage of income America’s top earners get to keep varies dramatically depending on which state they call home…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Across all states, the average tax burden for a single filer is approximately 36.1%, while the burden for a married couple is 28.8%, representing a savings of over 7% of total income.

    80% confidence

  • High earners in California face the nation's heaviest tax burden, losing 42.8% of their income if filing single and 35.8% if married.

    80% confidence

  • The combined weight of federal, state and FICA taxes can consume nearly half of a paycheck in some areas while leaving significantly more on the table in others.

    80% confidence

  • Connecticut has the highest average top 5% income at $691,840, while Mississippi has the lowest at $350,029, a difference of over $300,000.

    80% confidence

  • South Dakota provides the most tax-friendly environment for the top 5%, with burdens of only 31.3% (single) and 23.6% (married).

    80% confidence

  • There are nine states with no state income tax: Alaska, Florida, Nevada, New Hampshire, South Dakota, Tennessee, Texas, Washington and Wyoming.

    80% confidence

  • In states with no state income tax, the total tax burden for the top 5% is driven almost entirely by federal and FICA taxes, consistently keeping their total burden below the national average.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
How Much the Top 5% Pay in Taxes in Every State — Source | Via News | ViaNews Market